FDA Places Amgen's Obesity Drug AMG 513 Trial on Clinical Hold
Key Insights
Amgen disclosed during Q4 earnings that the FDA has placed their obesity (search) drug AMG 513 clinical trial on hold, though executives believe the issue is not related to the medication itself.
Regeneron Pharmaceuticals announced its first-ever quarterly dividend of $0.88 per share after 37 years, signaling confidence despite current commercial challenges with Eylea and Dupixent.
The development comes as Amgen continues late-stage testing of another obesity (search) treatment, MariTide, while working with regulators to determine a path forward for the AMG 513 study.
The Food and Drug Administration (FDA) has imposed a clinical hold on Amgen's obesity (search) drug study investigating AMG 513, the company revealed during its fourth quarter earnings announcement. While specific reasons for the hold were not disclosed, company executives expressed confidence that the issue is not directly related to the investigational medicine.
Impact on Amgen's Obesity Pipeline
The clinical hold represents a setback for Amgen's expanding presence in the competitive obesity (search) therapeutics market. Raymond James analyst Gary Nachman characterized the development as a "speed bump" in Amgen's obesity research and development efforts. The company maintains an active obesity pipeline, with another candidate, MariTide, currently progressing through late-stage clinical trials.
Amgen has not publicly detailed AMG 513's mechanism of action, maintaining strategic confidentiality around this aspect of the development program. Company representatives indicated that discussions are currently underway with regulatory authorities to establish a clear pathway for resuming the study.
Regeneron's Strategic Financial Move
In parallel developments within the biotech sector, Regeneron Pharmaceuticals marked a significant milestone by announcing its first dividend payment in its 37-year history. The company has instituted a quarterly cash dividend of $0.88 per share, coinciding with its fourth quarter earnings release.
Financial analysts have offered mixed interpretations of this strategic decision. Baird analyst Brian Skorney viewed the dividend announcement as a "positive surprise" with potential to broaden Regeneron's investor appeal, while noting it partially overshadowed concerns about underperforming sales of key products Eylea and Dupixent. Piper Sandler analyst Christopher Raymond interpreted the move as a "clear vote of confidence" from leadership, particularly notable during a period of commercial challenges.
Market Implications
The developments at both companies reflect the dynamic nature of the biotechnology sector, particularly in the increasingly important obesity (search) therapeutic space. While Amgen works to address the clinical hold on AMG 513, the company's continued advancement of MariTide demonstrates its commitment to maintaining a strong presence in obesity treatment development.